Start with sources
We look to research literature, study registries, and official material before weighing secondary claims. Trial records are checked against the public information available through ClinicalTrials.gov study records.
Independent by design
About
Ivoran is an independent resource on questions about ibogaine and Alzheimer’s disease. It prioritizes evidence limits, safety concerns, and clear context over speculation.
This resource exists for people affected by Alzheimer’s, caregivers, and anyone looking for grounded context around ibogaine-related claims.
Our editorial approach
A careful record, not a promise.
Ivoran organizes complex material so readers can see what is known, what remains uncertain, and why safety questions cannot be separated from evidence questions. The broader Ivoran resource on ibogaine and Alzheimer’s evidence and safety provides the starting point; this page explains how the resource is made.
We value usable context over confident-sounding conclusions.
Keep limits visible
Information is framed with attention to study design, missing data, and unanswered questions. Our wayfinding and topic organization is intended to help readers distinguish a signal from a conclusion.
Use plain language
We aim for terms that families can use without flattening uncertainty. When reference context is useful, we rely on established explanations such as the National Institute on Aging overview of Alzheimer’s disease.
What we cover
A set of questions, held in context.
The resource is organized around evidence, safety awareness, and the practical questions people bring to a difficult subject. It does not substitute general information for individualized medical or legal guidance.
Readers looking at claims around ibogaine and neuroplasticity can find that material placed alongside its limitations, while discussions of neuroregeneration questions are kept distinct from evidence of clinical benefit.
Some pages address the context often left out of simplified claims, including ibogaine half-life considerations and cardiac risk context. These topics are included to encourage careful reading, not to direct a personal course of action.
Who this is for
For readers who need room to think.
Ivoran is for people affected by Alzheimer’s, caregivers, and anyone seeking grounded context. It is also relevant to readers encountering adjacent conversations, including ibogaine’s anti-addiction claims, withdrawal-related questions, or discussion of ibogaine in fentanyl-related contexts.
Those subjects may overlap in public conversation, but they should not be treated as interchangeable. Our aim is to make the boundaries, uncertainties, and safety implications legible for non-specialist readers.
Where a term needs basic reference context, we prefer accountable sources, including the overview of evidence-based medicine, while keeping the central focus on what a source can and cannot support.
Editorial principles
The standards we return to.
These principles guide the way Ivoran selects, organizes, and explains material. They are deliberately simple so readers can see the posture behind the information.
- Evidence before hype.
- Safety awareness alongside every claim.
- Plain language without false certainty.
- Scientific humility where answers are incomplete.
- Independence from treatment provision and promotion.
Information should make uncertainty easier to see.
Ivoran is an independent information resource. It is not a clinic, medical provider, licensed treatment center, or legal authority, and its content is not medical or legal advice. Readers facing individual decisions should seek appropriate qualified guidance.
To understand the scope of the resource and how its pages are arranged, visit the independent dementia-focused ibogaine resource.
Contact Ivoran